Bsense Bio Therapeutics Ltd
Company Details
Status: Private
Employees: 1-10
Location:
2 Ilan ramon St, Ness-ziona, na 7403635, IL
Type:
sample
Technology:
sample
sample
sample
About: Bsense Bio Therapeutics is developing small molecules for the treatment of sensory hyperexcitability related disorders. Bsense is pioneering a novel approach targeting multiple hyperexcitability related mechanisms using a single compound, to achieve greater efficacy and safety.
Sensory neuron Hyperexcitability refers to a multitude of indications such as Pain, Pruritus, Tinnitus and seizure, in which sensory neurons are excessively active leading to dire clinical and quality of life ramifications for patients. These indications are considered as significant unmet medical needs representing a major healthcare burden.
Bsense Bio's approach is based on the targeting of two cation channels, a ligand-gated cation channel and a voltage-gated potassium channel, respectively, TRPV1 and Kv7.2/3, which are co-localized on sensory nociceptive neurons and are widely recognized as prominent players in the modulation of neuronal excitability. The company has generated preclinical proof-of-concept in chronic pain and has recently been generating data in additional hyperexcitability indications in the space of Pruritis and Tinnitus (some of which with Orphan disease designation).
The company is financed by Takeda Ventures Inc., OrbiMed Israel Partners, and Johnson & Johnson Innovation (JJDC), RMGP and the Israel Innovation Authority (IIA). Bsense was founded in September 2018 at the FutuRx biotech incubator based on technology that originated from Prof. Bernard Attali and Dr. Asher Peretz work from the Tel Aviv University.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Bsense Bio Therapeutics Ltd | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.